Revolution Medicines, Inc. Warrant
NASDAQ Global SelectTotal Valuation
Revolution Medicines, Inc. Warrant carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at -1.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.25B |
| Enterprise Value | -1.75B |
Share Statistics
Revolution Medicines, Inc. Warrant currently has 200.18M shares outstanding.
| Shares Outstanding | 200.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Revolution Medicines, Inc. Warrant maintains a current ratio of 6.80, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.44, indicating elevated leverage, while an interest coverage ratio of -38.51 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.80 |
| Quick Ratio | 6.59 |
| Debt / Equity | 10.44 |
| Debt / EBITDA | -0.11 |
| Interest Coverage | -38.51 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -59.39 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Revolution Medicines, Inc. Warrant's stock has gained approximately 2992.10526% over the past 52 weeks. The 50-day moving average sits at 4.25, while the 200-day moving average is 1.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 2992.10526% |
| 50-Day Moving Average | 4.25 |
| 200-Day Moving Average | 1.81 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -1.37B, while operating income came in at -1.39B.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -1.39B |
| Pretax Income | -1.37B |
| Net Income | -1.37B |
| EBITDA | -1.37B |
| EBIT | -1.39B |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Revolution Medicines, Inc. Warrant holds 1.91B in cash and equivalents against 156.63M in total debt, resulting in a net debt position of -440.94M. Total book value stands at -3.32B, with working capital of 1.68B providing operational flexibility.
| Cash & Cash Equivalents | 1.91B |
| Total Debt | 156.63M |
| Net Debt | -440.94M |
| Equity (Book Value) | -3.32B |
| Book Value Per Share | N/A |
| Working Capital | 1.68B |
Cash Flow
Revolution Medicines, Inc. Warrant produced -1.06B in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.06B |
| Capital Expenditures | -14.26M |
| Free Cash Flow | -1.07B |
| FCF Per Share | N/A |
Scores
Revolution Medicines, Inc. Warrant posts an Altman Z-Score of -3.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.30 |